1.0 INTRODUCTION The purpose of writing this report to understandings of mission across organizational subdivisions and the difficulty of regulating drug safety in a market context. Merck was established in the U.S. in 1891, but its roots trace back to Friedrich Jacob Merck’s purchase of a German drug store in 1668. Today the company is a top tier global entity, a “research-driven” pharmaceutical company “dedicated to putting patient’s ﬁrst.” Merck’s mission is to “provide society with superior products…that improve the quality of life and satisfy customer needs; provide employees with meaningful work…and investors with a superior rate of return.” As a long time player in the U.S. pharmaceutical industry, Merck has had extensive experience in assigning and dividing complex tasks among its many specialized departments. Specialization allows Merck to operate efﬁciently and bring new drugs to American patients. On May 20, 1999, the FDA approved Merck’s application to market Vioxx, a new arthritis pain-reliever.
As of 2004, surgical operations reached over seven thousand (7,000) per year, with a staff consisting of thirty-four (34) full-time nurses, ten (10) full-time surgeons, eight (8) part-time assistant surgeons and two (2) anesthesiologists, among other administrative and supporting staff to efficiently run both facilities. Strengths and Weaknesses The most identifiable strengths for Shouldice are the company’s brand image and their significant growth factors over time, considering demand for operations has exponentially increased since inception. Another realization stems from the founder’s successful techniques regarding the use of local anesthetic, the procedure itself and the facility design that inspires agility without harm to the patient. With this premature success, patients recover more rapidly, while being highly engaged in the process. Due to increasing demand for beds at Shouldice, and the low vacancy rate in return, the business is losing serious profits.
Its goal is to discover, develop, and successfully market innovative products to treat patients, ease suffering, and enhance the quality of life. Novartis is strengthening its medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines,and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of $37 billion(USD). “Succession planning had been in effect for a few years,” says Antoine Tirard, the global head of talent management for Novartis.
Compare and contrast the developments that led to one market drug launched in the mid-20th century and one launched in the past 25 years. Over a long period of time, the cost and the time taken for drug development has soared. The two examples that have been selected to compare and contrast are penicillin and sildenafil; where both have been arrived serendipitously. Penicillin discovery changed the course of medicine as the active ingredient that was discovered turned out to be an infection-fighting agent of enormous potency. The development of penicillin has served as the general model for most drug development and discovery during this specific time period.
Case Analysis for McKesson Corporation McKesson Corporation is one of the leading providers of pharmaceuticals, medical supplies, medical dispensing machines, and healthcare information technologies. The company is a leader in pharmaceutical distribution and healthcare information technology (www.YouSigma.com). There other business ventures that the McKesson participates in. The medication dispensing machines they manufacture are in commercial and some hospital pharmacies in the United States. This company has revenues in excess of 100 billion dollars.
The sales and market share growing steadily after every marketing campaign. Competition Situation Axe strong competitors in the personal care segment was Nivea (Beiersdorf AG), Colgate-Palmolive, and Old Spice (Procter & Gamble Co.). Another competitors on the market share were Avon Products Inc. and L’Oreal International. Marketing Mix Using these aspects, here are the marketing strategies of Axe: *
In 1923, Alexander Glenny perfected a method to inactivate tetanus toxin with formaldehyde. The same method was used to develop a vaccine against diphtheria in 1926. Pertussis vaccine development took considerably longer, with a whole cell vaccine first licensed for use in the US in 1948. Viral tissue culture methods developed from 1950-1985, and led to the advent of the Salk (inactivated) polio vaccine and the Sabin (live attenuated oral) polio vaccine. Mass polio immunisation has now eradicated the disease from many regions around the world.
Pfizer is the world's largest biological pharmaceutical company and their strategies has them moving with the times. With the numerous opportunities exposed to Pfizer, Inc., they want to take this advantage in putting forth their in-line products and business development, which may include acquisitions and joint adventures. With these business developments on the rise, they want to see growth in earnings, and increase their shareholder value. To achieve this, Pfizer must become organized when it comes to their strategic tactic when developing business opportunities. One particular area Pfizer is look at is therapeutic, which includes and not limited to are immunology and inflammation; neuroscience and pain oncology; cardiovascular, as well as establishing market products.
Its incremental expansion into the enormous global enterprise it is today was happening all the while – Teva’s history was riddled with merger after merger, as the firm’s market savvy view led it on the way to success. The swift and decisive acquiring of pharmaceutical companies – from Assia in the 1950s which then merged with Zori in 1963 and with Teva in 1968, through Ikapharm in the early 80s and 14 more international transactions from 1985 onwards – was in Teva’s DNA from the start. Early mergers immediately boosted sales, profits and market share, helping establish CEO Eli Hurvitz’s (1976-2002) view on the matter, by encouraging him to pursue additional purchases, basically basing Teva’s future growth plans on acquisitions. Mr. Hurvitz’s persistent push in the 1960s to consolidate the fragmented array of family-owned businesses which made up Israel’s pharmaceutical industry, resulted by the 80s in $50 million in revenue, with nowhere left to expand
The United States is known as the “hot bed of research and innovation in new medical technology”. (Shi, L. and Singh, D. 2001, p. 10). We have some of the best scientist and physicians that specialize in management of disease process. Daily, we continue strive to expand evidence base medicine to enhance patient outcomes and experiences. We focus on prevention and curative practice to slow or minimize the disease process.